Q4 2024 Management View CEO Raymond Tesi highlighted the transformative potential of 2024 for INmune Bio, emphasizing upcoming milestones. He noted the Phase 2 trial of XPro for Alzheimer's disease, ...

Pulse Biosciences, Inc. ( NASDAQ: PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of ...

Plus Therapeutics' Q4 2024 earnings reveal progress with REYOBIQ nearing FDA approval & CNSide's 2025 launch. Key hires & funding bolster milestones.

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

At least 14 million children are expected to face disruptions to essential nutrition support and services in 2025 because of ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

If we want to turn these short-term gains into sustainable change, we must fully unleash the potential of methadone-assisted ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

Non-drug approaches can help people cope with stress and despair, says an expert. Read more at straitstimes.com.

Trauma can be a life-altering experience that leaves deep emotional, physical, and psychological scars. It can shake an ...